In 2025, IPC advanced the priorities outlined in our strategic plan, strengthening research collaboration, expanding regional education, and progressing focused clinical initiatives that address real-world gaps in psoriasis care. This encompassed ongoing efforts in disease severity reclassification, defining topical failure, examining cardiometabolic impacts on psoriasis, addressing complex clinical scenarios, commencing development of a comprehensive textbook on psoriasis, and delivering continued regional education via our Masterclasses.
Throughout the year, our Board Members, Councilors, and Jr. Councilors led scientific discussions, educational programming, and collaborative initiatives that reflect IPC’s role as a global network of physician experts. From international symposia to clinical guidance efforts, these contributions continue to shape how psoriasis care evolves across regions.
We are grateful to the many individuals and partners who volunteer their time, expertise, and leadership to IPC’s work. Their contributions are reflected throughout the progress summarized in this report.
We invite you to view the Annual Report below to learn more about IPC’s work in 2025.
Thank you for your continued engagement and partnership
Bruce Strober, MD, PhD
President
Christy Langan
Chief Executive Officer
IPC Councilor Helen Young provides commentary on a study identifying skin-derived myeloid precursors and CD200+ fibroblasts as key drivers of psoriatic disease spread from the skin to joints, highlighting the CD200–CD200R1 axis as a promising therapeutic target.
IPC Fellow Dr. Yemsrach Abawaji shares her firsthand perspective on the barriers to psoriasis diagnosis and treatment in Ethiopia and opportunities to improve care.
Did you miss the IPC symposium at the 83rd Society for Investigative Dermatology (SID) Annual Meeting? Select session videos are now available. The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure covered early intervention strategies, treatment selection, immune pathway targeting, PsA prevention, clinical escape, and real-world cases that inform long-term psoriasis care.
Depression affects approximately 20% of patients with psoriasis, five times the rate seen in the general population. IPC Jr. Councilor Mio Nakamura, MD, MS, FAAD, walks through the bidirectional relationship between psoriasis and depression, the shared inflammatory pathways driving both conditions, and practical guidance on screening and incorporating multidisciplinary mental health support into psoriasis management.
